Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

8:51 AM ET 10-Q
Financial Results Yan Chuang Group Inc.

Yan Chuang Group Q1 2026 Results: Net Loss of $26.7K, Loss Widens

Yan Chuang Group Inc. is a startup fintech company that has not yet generated revenue and reported a net loss of $26,715 for the quarter ended September 30, 2026. The company significantly increased its cash position to $626,089 through the issuance of common stock, though management expressed concerns regarding its ability to continue as a going concern without further capital.

Key figure
Net loss $26.7K
8:48 AM ET 8-K
M&A Deal WEN Acquisition Corp WENN

WEN Acquisition Signs $1B M&A Deal with Our Next Energy Inc.

Wen Acquisition Corp (WENN), a SPAC, has entered into a definitive business combination agreement with Our Next Energy Inc. (ONE), a U.S.-based LFP battery manufacturer. The transaction values the combined company at a pro forma equity value of approximately $1 billion and is expected to provide up to $400 million in gross proceeds, including a $100 million PIPE. Upon closing in the first half of 2027, the combined company will be named Our Next Energy Holdings, Inc. and is expected to trade on Nasdaq under the ticker ONEE.

Value
$1B
Counterparty
Our Next Energy Inc.

“Over the last five years, LFP has grown from roughly 20% to 60% of the global battery market, yet China produces approximately 99% of the world’s LFP cells. We built ONE to close that gap with a secure American and allied supply chain. We believe our combination with Wen will give us a public platform to scale ONE into this $40B addressable market with access to growth capital as we scale our operations to meet rising demand.”

Mujeeb Ijaz, Founder and CEO of ONE

“ONE has done the hard part of building an American LFP cell and pack business, with factories operating and customers in markets that increasingly require domestic supply. With two operating factories, binding customer contracts, and federal policy appearing to move its way, ONE is positioned to lead the reshoring of critical battery manufacturing in the United States.”

Julian Sevillano, CEO of Wen
8:46 AM ET 8-K
Business Update Bitmine Immersion Technologies, Inc. BMNR

Bitmine Immersion Technologies Business Update

Bitmine Immersion Technologies provided an operational update disclosing total crypto, cash, and marketable securities holdings of $11.8 billion. The company's treasury now includes 6.08 million ETH tokens, representing 4.97% of the total ETH supply, as part of its ongoing 'Alchemy of 5%' accumulation strategy.

8:42 AM ET 8-K
Financial Results Ainos, Inc. AIMD

Ainos Financial Results

Ainos reported Q3 2026 financial results with revenue increasing significantly to $642,889, driven by VELDONA licensing and AI Nose semiconductor programs. The company narrowed its GAAP net loss by 36% year-over-year and highlighted a subsequent $9 million follow-on order for its AI Nose systems.

“Our third-quarter results show progress in translating commercial agreements into revenue. Revenue reached $642,889, up 29,567% year over year, driven by VELDONA licensing and our AI Nose semiconductor program. We delivered 1,400 AI Nose systems under our initial $2.1 million agreement and received initial orders from another semiconductor customer.”

Eddy Tsai, Chairman, President and Chief Executive Officer

“Our Q3 2026 results demonstrate progress in both revenue generation and operating discipline. GAAP net loss improved 36% year over year while non-GAAP adjusted net loss improved 51%. GAAP gross margin increased to 83.4% from 78.0% in the third quarter of 2025, while non-GAAP gross margin increased to 83.6% from 78.0%, excluding share-based compensation and depreciation and amortization allocated to cost of revenue.”

Christopher Lee, Chief Financial Officer of Ainos
8:42 AM ET 10-Q
Financial Results Aptevo Therapeutics Inc. APVO

Aptevo Therapeutics Q3 2026 Results: Net Loss of $6.55M, Loss Narrows

Aptevo Therapeutics reported a net loss of $6.5 million for the quarter ended September 30, 2026, and a net loss attributable to common stockholders of $9.3 million after accounting for a $2.8 million deemed dividend. The company's cash position decreased significantly from $21.6 million at the end of 2025 to $8.3 million as of September 30, 2026, primarily due to $19.1 million used in operating activities.

Key figure
Net loss $6.55M
8:41 AM ET 8-K
M&A Deal John Marshall Bancorp, Inc. JMSB

John Marshall Bancorp M&A Deal with Eagle Financial Services, Inc.

John Marshall Bancorp and Eagle Financial Services announced that the Federal Reserve Bank of Richmond has approved the merger of their respective bank subsidiaries, Bank of Clarke and John Marshall Bank. The transaction, originally announced in September 2026, will create a combined community bank with approximately $4.3 billion in total assets. The deal remains subject to approval from the Virginia Bureau of Financial Institutions and shareholders of both companies.

Counterparty
Eagle Financial Services, Inc.
8:41 AM ET 8-K
M&A Deal Eagle Financial Services Inc EFSI

Eagle Financial Services M&A Deal with John Marshall Bancorp, Inc.

Eagle Financial Services, Inc. (EFSI) and John Marshall Bancorp, Inc. (JMSB) announced that the Federal Reserve Bank of Richmond has approved the merger of Bank of Clarke into John Marshall Bank. The transaction, originally announced in September 2026, will create a combined community bank with approximately $4.3 billion in total assets. The deal remains subject to approval from the Virginia Bureau of Financial Institutions and shareholders of both companies at meetings scheduled for November 19, 2026.

Counterparty
John Marshall Bancorp, Inc.
8:40 AM ET Form 4
Insider Buying Donegal Group Inc DGICB

Donegal Group Insider Donegal Mutual Insurance Co Buys $285K of Stock

Donegal Mutual Insurance Co bought 15,000 shares of Donegal Group Inc at $18.94 to $19.01 a share (average $18.98) in 2 transactions, worth $285K in total between Nov 12, 2026 and Nov 13, 2026. Shares held after the trade: 14,472,628 (+0.1%).

Value
$285K
Shares
15,000
Average price
$18.98
Holding change
+0.1%
Trade date
Nov 12, 2026 to Nov 13, 2026
8:39 AM ET 8-K
Investor Meeting Columbia Financial, Inc. CLBK

Columbia Financial Investor Meeting

Columbia Financial management will participate in investor meetings hosted by Piper Sandler on November 17 and 18, 2026. The company will discuss a presentation that will be made available on its Investor Relations website.

Counterparty
Piper Sandler
8:39 AM ET 8-K
Clinical Trial Data Rein Therapeutics, Inc. RNTX

Rein Therapeutics Clinical Trial Data

Rein Therapeutics announced preliminary blinded Phase 2 data from its RENEW trial evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF). The data showed that 33% of evaluable patients demonstrated improvement in forced vital capacity (FVC) at Week 12, with favorable safety and tolerability observed across the study population.

“As we continue to enroll patients in the study, today’s blinded look at the data shows encouraging lung function trends and a favorable safety and tolerability profile across the study population, reinforcing our confidence in the potential of LTI-03 to deliver a differentiated clinical and safety profile for patients with significant unmet need.”

Brian Windsor, Ph.D., President and Chief Executive Officer
8:37 AM ET 8-K
Loan & Debt Crh Public Ltd Co CRH

Crh Public Ltd Debt Financing Update

CRH Finance DAC, a subsidiary of CRH plc, completed the issuance and sale of €750 million 4.250% Notes due 2033 and €750 million 4.625% Notes due 2038. The notes are fully guaranteed by CRH plc and were issued under a €10 billion Euro Medium Term Note Programme. Net proceeds are intended for general corporate purposes.

8:36 AM ET 8-K
Financial Results Canton Strategic Holdings, Inc. CNTN

Canton Strategic Holdings Financial Results

Canton Strategic Holdings reported its third quarter 2026 financial results, achieving its first positive Adjusted EBITDA of $0.6 million. Total revenue grew 104% sequentially to $3 million, driven by the first full quarter of Super Validator and locking-as-a-service operations. The company reported a net loss of $35.1 million, primarily reflecting non-cash items as it continues to scale its Canton Network strategy.

“We are proud to have achieved our first positive Adjusted EBITDA this quarter, a notable milestone as we mark the first year of operations since our launch in November 2025. With a full year under our belt as a publicly traded company operating our CC strategy, we remain focused on growth. Our Super Validator operations and locking-as-a-service offering allow us to support the Canton Network and its participants while also earning revenue that we can deploy for continued investment in the ecosystem and enhanced value for shareholders. With our operating cost base largely fixed and clear visibility to additional approved Super Validator weight, we believe the business is positioned for significant operating leverage and margin expansion.”

Mark Wendland, Chairman and Chief Executive Officer
8:36 AM ET 8-K
Financial Results Cycurion, Inc. CYCU

Cycurion Financial Results

Cycurion reported record quarterly revenue of $5.4 million for Q3 2026, a 40% increase year-over-year, driven by recent acquisitions and a return to growth in existing operations. Gross profit increased more than sevenfold to $1.9 million, while the company's operating loss narrowed by 35% to $3.0 million.

Term
Q3 2026

“Our third-quarter results demonstrate the momentum we are building at Cycurion. Higher-margin revenue translated into substantially more gross profit, and we narrowed our operating and adjusted EBITDA losses. We also returned to revenue growth in our existing operations while adding contributions from our acquisitions. We are encouraged by this progress and focused on carrying it forward.”

L. Kevin Kelly, Chairman and Chief Executive Officer

“We see a significant opportunity ahead. Our acquisitions have expanded our capabilities and customer reach, and our predictive intelligence strategy gives us more ways to help customers identify and address their most consequential threats. Our team, which includes veterans of the U.S. Intelligence Community and the private-sector cybersecurity industry, is focused on converting those opportunities into recurring revenue, stronger gross profit and continued progress toward profitability. We are building on a stronger operating foundation while maintaining expense discipline and working to improve operating cash flow.”

L. Kevin Kelly, Chairman and Chief Executive Officer
8:36 AM ET 8-K
Financial Results StableCoinX Inc. USDE

StableCoinX Financial Results

StablecoinX reported its third quarter 2026 financial results, highlighting a 666% sequential revenue increase to $0.48 million driven by its Decentralized Verifier Node (DVN) infrastructure. The company reported a GAAP net loss of $100.2 million, primarily due to non-cash warrant liability adjustments, while its ENA token treasury was valued at approximately $802 million at quarter-end.

Term
Q3 2026

“Our third quarter performance provided an initial indication of the value StablecoinX was built to deliver. Our verifier infrastructure doubled its cumulative verified volume to more than $6 billion in less than two months, which increased revenue nearly eightfold sequentially.”

Christopher Jensen, Chief Executive Officer
8:35 AM ET 8-K
Financial Results Aptevo Therapeutics Inc. APVO

Aptevo Therapeutics Financial Results

Aptevo Therapeutics reported financial results for the third quarter ended September 30, 2026, and provided a business update on its clinical pipeline. The company highlighted a 79% remission rate for its lead candidate mipletamig in high-risk TP53-mutated AML patients, which is nearly double the historical benchmark for standard-of-care treatments.

“We are entering an exciting period for Aptevo, with growing clinical evidence that reinforces our confidence in mipletamig and meaningful progress across our broader pipeline. We are seeing strong clinical activity in patients with some of the most difficult-to-treat forms of AML, patients advancing to potentially curative stem cell transplantation, and important improvements in tolerability.”

Jeff Lamothe, President and Chief Executive Officer of Aptevo

“As we approach important clinical and development milestones, we believe Aptevo is increasingly well positioned to translate the strength of our science into meaningful opportunities for patients and long-term value for shareholders.”

Jeff Lamothe, President and Chief Executive Officer of Aptevo
8:35 AM ET 8-K
Capital Raise Super League Enterprise, Inc. SLE

Super League Enterprise Capital Raise of $600K

Super League Enterprise, Inc. entered into a securities purchase agreement with accredited investors for a registered direct offering of 150,000 shares of common stock. The offering is priced at $4.00 per share and is expected to result in gross proceeds of approximately $600,000. The transaction is conducted under the company's existing shelf registration statement and is scheduled to close around November 16, 2026.

Value
$600K
Counterparty
certain accredited investors
8:34 AM ET 8-K
Loan & Debt Freeport-Mcmoran Inc FCX

Freeport-Mcmoran Debt Financing Update

PT Freeport Indonesia (PTFI), a 48.76% owned subsidiary of Freeport-McMoRan, announced its intention to offer one or more series of U.S. Dollar denominated senior unsecured notes. The proceeds from the offering are intended to refinance existing indebtedness and for general corporate purposes. The notes will be included in Freeport-McMoRan's consolidated debt once issued.

8:34 AM ET 10-Q
Financial Results Professional Diversity Network, Inc. IPDN

Professional Diversity Network Q3 2026 Results: Net Loss of $2.41M, Loss Widens

Professional Diversity Network reported a total revenue of $3.44 million for the nine months ended September 30, 2026, a decrease from $4.61 million in the prior year. The company experienced a net loss of $5.98 million during this period, driven by significantly higher depreciation and amortization expenses and a decline in recruitment services revenue.

Key figure
Net loss $2.41M
8:33 AM ET 10-Q
Financial Results Larimar Therapeutics, Inc. LRMR

Larimar Therapeutics Q3 2026 Results: Net Loss of $31.1M, Loss Narrows

Larimar Therapeutics reported a net loss of $31.1 million for the third quarter of 2026, an improvement from the $47.7 million loss in the prior year period, primarily driven by a significant decrease in research and development expenses. The company strengthened its balance sheet through equity issuances, ending September 30, 2026, with $128.7 million in cash, cash equivalents, and marketable securities.

Key figure
Net loss $31.1M
8:33 AM ET 8-K
Financial Results Professional Diversity Network, Inc. IPDN

Professional Diversity Network Financial Results

Professional Diversity Network reported Q3 2026 financial results, showing a 48.2% revenue decline to $0.86 million, primarily due to reduced demand in its TalentAlly and RemoteMore segments. Despite the revenue drop, the company improved its working capital to $0.2 million and launched a new GPU computing initiative through PDN Intelligence, Inc. to enter the AI infrastructure market.

Term
Q3 2026

“Our third quarter results reflect our continued focus on financial discipline, operational efficiency, and strategic business development. We have made meaningful progress in strengthening our working capital position and managing operating expenses while continuing to explore new growth opportunities.”

Bella Gu, Chief Executive Officer and Chief Financial Officer

“The launch of our graphics processing unit (“GPU”) computing initiative through PDN Intelligence, Inc. represents an important step in our strategy to expand into artificial intelligence (“AI”) infrastructure and computing services.”

Bella Gu, Chief Executive Officer and Chief Financial Officer
8:32 AM ET 10-Q
Financial Results HeartCore Enterprises, Inc. HTCR

HeartCore Enterprises Q3 2026 Results: Net Loss of $601K

HeartCore Enterprises reported a significant decline in revenue to $269,852 for the nine months ended September 30, 2026, compared to $1,666,519 in the prior year, resulting in a net loss of $3,792,658. The company underwent a 1-for-20 reverse stock split on April 2, 2026, and is currently managing the disposal of discontinued operations.

Key figure
Net loss $601K
8:32 AM ET 8-K
Business Update Microbot Medical Inc. MBOT

Microbot Medical Business Update

Microbot Medical provided a third quarter 2026 operational update highlighting a 44% sequential increase in procedure utilization for its LIBERTY Endovascular Robotic System. The company ended the quarter with $62 million in cash and expanded its commercial footprint to 12 customer accounts and 10 sales territories.

8:32 AM ET 8-K
Stock Buyback Empery Digital Inc. EMPD

Empery Digital Stock Buyback Update

Empery Digital Inc. repurchased 194,625 shares of its common stock during the week ended November 13, 2026, at an average price of $2.09 per share. These transactions were part of an existing $200 million share repurchase program, which now has approximately $49 million in remaining authorization.

8:32 AM ET 8-K
Capital Raise Arcturus Therapeutics Holdings Inc. ARCT

Arcturus Therapeutics Holdings Capital Raise of $50M

Arcturus Therapeutics entered into a securities purchase agreement with Meiji Seika Pharma for the sale of 2,466,395 shares of common stock at $20.27 per share, raising $50 million in gross proceeds. The investment was made at an 80% premium to the 30-day average closing price and is part of an expanded collaboration including a license agreement for ARCT-154 technology and a pandemic preparedness MOU in Japan.

Value
$50M
Counterparty
Meiji Seika Pharma Co., Ltd.

“The investment, together with the license agreement and the pandemic preparedness MOU, reflects Meiji’s confidence in our development capabilities and the potential of our technology platform.”

Joseph Payne, President and Chief Executive Officer of Arcturus Therapeutics
8:32 AM ET 8-K
Financial Results HCW Biologics Inc. HCWB

HCW Biologics Financial Results

HCW Biologics reported financial results for the third quarter of 2026, highlighting progress in its HCW9302 Phase 1 clinical study for alopecia areata and the presentation of its TRBC platform molecules at SITC2026. The company recently secured up to $10.0 million in debt financing to support its clinical and preclinical programs through the Phase 1 readout expected in Q1 2027.

Term
Q3 2026

“Progress continues steadily for our clinical study evaluating HCW9302 in alopecia areata, and we are encouraged by results in humans that are consistent with our preclinical studies. We have the support of strong clinical sites who share our passion for developing breakthrough immunotherapeutics. With the addition of a third clinical site, we are hopeful that patient enrollment will maintain a good momentum as we come to the end of the Phase 1 clinical study. We are also excited about the great progress we have made with the molecules we have constructed using our TRBC platform, especially our lead T-cell engager, HCW11-018b, and our lead second-generation immune-checkpoint inhibitor, HCW11-040, which have the potential of revolutionizing treatment for solid tumors and senescence-associated diseases.”

Dr. Hing C. Wong, the Company’s Founder and Chief Executive Officer
8:31 AM ET 10-Q
Financial Results Virginia National Bankshares Corp VABK

Virginia National Bankshares Q3 2026 Results: Net Income $6.56M, Up 43.3% YoY

Virginia National Bankshares Corp reported net income of $6.6 million for the third quarter of 2026, a significant increase from $4.6 million in the same period of 2025. This growth was driven by higher net interest income and a $4.7 million gain on the sale of a limited partnership investment during the nine-month period.

Key figure
Net income $6.56M · +43.3% YoY
8:31 AM ET 10-Q
Financial Results HCW Biologics Inc. HCWB

HCW Biologics Q3 2026 Results: Net Loss of $3.22M, Loss Narrows

HCW Biologics Inc. reported a significant revenue increase to $6.7 million for the nine months ended September 30, 2026, primarily driven by a $3.5 million noncash licensing agreement. Despite this, the company recorded a net loss of $5.0 million for the period and an accumulated deficit of $113.5 million, reflecting ongoing research and development costs and substantial equity dividends to investors.

Key figure
Net loss $3.22M
8:31 AM ET 8-K
Financial Results RenX Enterprises Corp. RENX

RenX Enterprises Financial Results

RenX Enterprises reported record Q3 2026 revenue of $4.48 million, representing 27.5% year-over-year growth and its third consecutive quarter of sequential growth. The company achieved a record gross margin of 34.3% and completed construction of its Microtec mill, with production expected to begin in January 2027.

Term
Q3 2026

“RenX grew revenue every quarter of 2026, expanded gross margin to its best level of the year, and delivered a third straight profitable quarter in Logistics. That is fundamental growth, quarter after quarter, generated by operations.”

David Villarreal, Chief Executive Officer of RenX Enterprises Corp.
8:30 AM ET Form 4
Insider Buying Perspective Therapeutics, Inc. CATX

Perspective Therapeutics Director Robert F. Williamson III Buys $15.6K of Stock

Robert F. Williamson III, Director, bought 18,609 shares of Perspective Therapeutics, Inc. at $0.84 a share, worth $15.6K in total on Nov 12, 2026. Shares held after the trade: 28,473 (+188.7%).

Value
$15.6K
Shares
18,609
Price
$0.8400
Role
Director
Holding change
+188.7%
Trade date
Nov 12, 2026
8:30 AM ET Form 4
Insider Buying Perspective Therapeutics, Inc. CATX

Perspective Therapeutics Director Frank Morich Buys $15K of Stock

Frank Morich, Director, bought 15,000 shares of Perspective Therapeutics, Inc. at $0.9971 a share, worth $15K in total on Nov 12, 2026. Shares held after the trade: 15,000.

Value
$15K
Shares
15,000
Price
$0.9971
Role
Director
Trade date
Nov 12, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.